MRC-Holland - About us - Careers - EN

new products
P339-SHANK3 Autism Spectrum Disorder
P010-POLG Mitochondrial maintenance
P366-CHM-RP2-RPGR Retinitis pigmentosa (RP)
P350-CLCN1-KCNJ2 Myotonia congenita, Thomsen’s disease, Becker’s disease, Andersen-Tawil syndrome
P273-PCSK5 Atherosclerotic cardiovascular disease (risk of)

improved products
P044-NF2 Neurofibromatosis type 2 (NF2)
P199-HEXA Tay-sachs disease
P214-COL2A1 Skeletal disorders, Achondrogenesis, Chondrodysplasia, Early onset familial Osteoarthritis, SED congenital, Langer-Saldino achondrogenesis, Kniest dysplasia, Stickler syndrome, Spondyloepimetaphyseal
P280-SLC26A4 Pendred syndrome
P026-Sotos Sotos syndrome
ME011-MMR Mismatch repair genes (MMR)

Are you looking for a job?

Klik hier voor de Nederlandse versie

MRC-Holland is a fast-growing biotechnology company based in the Amsterdam Baarsjes. MRC-Holland consists of a multinational team of about 35 employees. MRC-Holland is the inventor of the Multiplex Ligation-dependent Probe Amplification (MLPA) technique, a sensitive method to detect copy number changes in genes. MLPA is used in numerous applications, from identifying hereditary diseases to investigating genetic alterations in tumors. Our MLPA products are used in hundreds of labs and hospitals worldwide

To meet the continuously-growing demand for new MLPA applications, we are looking for new colleagues:

Junior Scientist (full time)

Newsletter

Home

Site map

Terms and Conditions